RETREG1 and neoplasm: The analysis further revealed a total of tumor antigens including FAM134B, ALDH3A2, SAV1, RORC, and FN1, which were considered as significant candidates for the MESO-mRNA vaccine that could have immune provocative effects and be both presented and processed by APCs for a tumor response induction.